- Conditions
- Autism Spectrum Disorder
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 152
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Metastatic Cancer
- Interventions
- capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York • Cleveland, Ohio
- Conditions
- Decompression Sickness
- Interventions
- Sodium Chloride 0.9% Inj pre-exposure, Sodium Chloride 0.9% Inj post-exposure, Recombinant human plasma gelsolin pre-exposure, Recombinant human plasma gelsolin post-exposure, Hyperbaric chamber
- Drug · Other
- Lead sponsor
- BioAegis Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Postoperative Delirium, Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
- Interventions
- Dextrose Water, Caffeine citrate
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Rhinitis, Sinusitis
- Interventions
- Quinine Sulfate, Placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- SARS CoV 2 Infection, Pneumonia
- Interventions
- SP16 (6mg), Placebo, SP16 (12 mg)
- Drug · Other
- Lead sponsor
- Serpin Pharma, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Healthy Volunteers
- Interventions
- Sucralose, Aspartame, Acesulfame-Potassium, Control
- Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Weight Management, Stress
- Interventions
- Ashwagandha 300 mg standardized root extract, Identical placebo capsule.
- Dietary Supplement · Other
- Lead sponsor
- SF Research Institute, Inc.
- Network
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Heart Failure
- Interventions
- CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tustin, California
- Conditions
- Cancer
- Interventions
- Dabrafenib, Trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
- Conditions
- Hyperkalaemia
- Interventions
- Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level, Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1), Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2), Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3), Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 0 Years to 18 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more
- Conditions
- Leukemia, Acute Lymphocytic Leukemia
- Interventions
- Everolimus (RAD001), Cyclophosphamide, Vincristine, Doxorubicin, Dexamethasone, Mesna, Methotrexate, Ara-C (Cytarabine), Methylprednisone, G-CSF
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Heart Failure
- Interventions
- Vepoloxamer, 5% dextrose in water
- Drug · Other
- Lead sponsor
- Mast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Tupelo, Mississippi
- Conditions
- Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Interventions
- Hydrogen water
- Dietary Supplement
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Post-partum, Women
- Interventions
- Creatine Monohdyrate
- Dietary Supplement
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Alcohol Use Disorder
- Interventions
- alcohol, Stress-Induction, PT150
- Drug · Behavioral
- Lead sponsor
- Pop Test Oncology LLC
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
- Interventions
- Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumor
- Interventions
- paclitaxel, TAK-228, TAK-117
- Drug
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Decitabine, Venetoclax, FHD-286
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
- Interventions
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine, Aldesleukin
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Tuberculosis
- Interventions
- PA-824 1000 mg
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- Tacrolimus ophthalmic solution
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Miami, Florida • Waltham, Massachusetts + 3 more
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma, Bladder Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland